Preview

Артериальная гипертония на фоне избыточного веса: особенности терапевтического подхода

https://doi.org/10.14341/2071-8713-5264

Полный текст:

Список литературы

1. Julius S, Gudbrandsson T, Jamerson K, Shahab ST, Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens. 1991;9:983-6.

2. Reaven GM, Lithel H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadreal system. N Engl J Med. 1996;334:374-81.

3. Ernsberger P, Damon TH, Graff LM, Shafer SG, Christen MO. Moxonidini, a centrally acting antithypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ter. 1993;624:172-92.

4. Van Zwieten PA. Central imidazoline (I1) receptors as targets of centrally acting antithypertensives:moxonidine and rilmenidine. J Hypertens. 1997;15:117-25.

5. Likungu J, Molderings GL, Gothert M. Presynaptic imidazoline receptors and alpha2-adrenoceptors in the human heart:discrimination by anclonidine and moxonidine. Nauyn Schmiedebergs. Arch Pharmacol. 1996;354:689-92.

6. Wimann H.-J., Rudolph M. Clinical phrmacokinetics of moxonidine. J. Cardiovacs Pharmacol. 1992;20:S37-S41.

7. Haenni A., Lithel H. Moxonidine improves insuslin resistance in obese, insulinresistant patients with moxonidine. J Hypertens. 1999;17(Suppl):S24-S35.

8. Mitrovic V et al. Hemodynamic and neurohumonal effects of moxonidine in patients with essential hypertension. Cardiovasc Drug Ther. 1991;5:967-72.

9. Frei M, Kuster L, Gardosh von Krosigh P-P, Koch HF. Moxonidine and hydrochlorothiazide in combination:a synergistic antithypertensive effect. J Cardiovasc Pharmacol. 1994;24(Suppl 1):S25-S28.

10. Prichard BNC, Simmons R, Rooks M, Haworth DA and al. A double-blind comparison of moxonidine and atenolol in the management of patiens with mild-tomoderate hypertension. J Cardiovasc Pharmacol. 1992;24 (Suppl 4):S45-S49.

11. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mildtomoderate hypertension:moxonidine versus captopril. J Cardiovasc Pharmacol 1994;24 (Suppl 1):S29-S33.

12. Kuppers HE. et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens. 1997;15:93-7.

13. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol. 1992;20 (Suppl 4):S42-S44.

14. Waters J, Ashford J, Jager B et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC Study. J. Clinical Basic Cardiol. 1999;2:219-224.

15. Rosen P, Ohly P, Gleichman H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose fed rat. J Hypertens. 1997;15 (Suppl):S31-S38.

16. Lithell H. Selective improvement in insulin sensitivity with moxonidine Report from Satellite Symposium of XIX Congress of Eur. Soc. Cardiology. Stockholm. 1997;1-8.

17. Celermajer DS, Sorensen KE, Gooch VM. et al. Non-invasive detection of endothelial dysfunction on children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-5.

18. Ernsberger P., Ishizuka T., Liu S., et al. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rats. J. Pharmac Exp Therap. 1999;288:139-147.

19. И.Е. Чазова, В.Б. Мычка. Метаболический синдром. М.: Медиа Медика, 2004. 168 с.

20. Freidman J.E., Ishizuka T., Liu S. Antihyperglycemic activity of moxonidine:metabolic and molecular effects of obese spontaneously hypertensive rats. Blood pressure. 1998;7 (Suppl 3):32-39.

21. Ernsberger P., Ishizuka T., Liu S., et al. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rats. J. Pharmac Exp Therap. 1999;288:139-147.

22. Haenni A., Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertension. 1999;17 (suppl 3):S29-S39.

23. Алмазов В.А., Благосклонная Я.В., Шляхто Е.В. с соавт. Роль абдоминального ожирения в патогенезе синдрома инсулинорезистентности. Тер. Архив 1999;10:20-24.

24. Соколова Л.А., Русанов О.А., Винник Т.А. с соавт. Влияние моксонидина на показатели геодинамики и уровень инсулина крови у больных мягкой и умеренной артериальной гипертензией (результаты 6 - месячной терапии). Артериальная гипертензия. 2000;6(1):59-62.

25. D. John. Betteridge Risk Management with Moxonidine: Focus on ALMAZ and Other Trials in Insulin Resistance, ESC 2004.

26. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome:a postmarketing surveillance study. J Hum Hypertens. 2004 Sep;18 (9):669-75.

27. A.F. Sanjuliani, V. Genelhu de Abreu, J. Ueleres Braga, E.A. Francischetti Effects of Moxonidine on the Sympathetic Nervous System, Blood Pressure, Plasma Renin Activity, Plasma Aldosterone, Leptin, and Metabolic Profile in Obese Hypertensive Patients. Journal of Clinical and Basic Cardiology. 2004;7(Iss 1-4):19-25.


Для цитирования:


Mychka V.B., Masenko V.P., Chazova I.E. Артериальная гипертония на фоне избыточного веса: особенности терапевтического подхода. Ожирение и метаболизм. 2006;3(3):46-50. https://doi.org/10.14341/2071-8713-5264

For citation:


., ., . Arterial'naya gipertoniya na fone izbytochnogo vesa: osobennosti terapevticheskogo podkhoda. Obesity and metabolism. 2006;3(3):46-50. (In Russ.) https://doi.org/10.14341/2071-8713-5264

Просмотров: 17


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)